What a wonderful meeting and unforgettable moments. Thanks 🙏 mates for your visit to MD Anderson Cancer Center Madrid Hospiten Science 🧬 connect people 😊 ESMO - Eur. Oncology OncoAlert

The overall survival already has many events, almost the planned amount for a full analysis. And differences in presented endpoints are pratically irrelevant clinically. Especially because of the weak control arm. We need much more for the price.

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Terrific session about access and how to improve care #gureview23 LACOG - Latin American Cooperative Oncology Group Touching the point. Payers, providers, pharma, government, advocacy and medical societies are important players to improve care and decrease disparities. Research has an important role Diogo Rodrigues

Será que a gente consegue que essa pérola rubro-negra chegue nos jovens torcedores?

Cumprindo um papel social como oncologista, falando sobre a incidência do câncer no Brasil youtu.be/IQJ3cmz5K60?si… via YouTube

Understanding the complexity of p53 in a new era of tumor suppression dlvr.it/T85Rzy

O que está acontecendo com a UNIMED Campinas? linkedin.com/posts/andre-sa…

Ué… achei que era o padrão. Taí o Weverton no primeiro jogo que não me deixa mentir…

A hipocrisia do equilíbrio esportivo do campeonato brasileiro: o curioso caso de Flamengo x Internacional Em um campeonato qualquer, o objetivo é que todos os competidores tenham as mesmas oportunidades para se tornarem campeões, mesmo que se saiba que isso não é possível. O

Que atuação tiveram Luiz Araújo e Léo Pereira! O segundo gol foi a apoteose disso. Atuação do Flamengo passava por aproveitar os espaços entre as linhas do Bolivar, e o fez muito bem enquanto teve um 9 de referência em campo. Com Pedro e também com Carlinhos, o Flamengo

spoti.fi/3STlvEa Converso com meus amigos e oncologistas David, Higor e Isabela sobre os cânceres mais incidentes.

Um "esquema Ponzi" é um tipo de fraude financeira em que os rendimentos prometidos aos investidores são pagos com o dinheiro de novos investidores, em vez de serem gerados por algum tipo de lucro legítimo ou investimento real. O esquema depende constantemente da entrada de novos

Outstanding talk from silke gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 ESMO - Eur. Oncology OncoAlert UroToday.com

SPLASH phase III data of Lu PNT2002 vs alternate Arpi ( again 🙄) makes more like a splish than a big splash .. not convinced that as designed it contributes to therapeutic improvements in mCRPC but definitely there is opportunity if compared to an actually active agent and

Contact-02 final analysis results are underwhelming .. the combo of atezo / Cabo was investigated in an aggressive subset of mCRPC no benefit overall survival with some hypothesis generating findings in men with liver Mets . Kudos to Neeraj Agarwal, MD, FASCO but we have to dig deeper to

About CONTACT-02 study. While I respect the hard work and dedication of the investigators and congratulate them (specially Neeraj Agarwal, MD, FASCO) on conducting the trial, this is clearly a negative study. We have to acknowledge it as such. It seems we are regressing in critical thinking,

NIAGARA is the first randomized trial to demonstrate significant OS difference in the NIBC perioperative trest. #ESMO24 Tom Powles did it again!!! Another practice changing trial in the back OncoAlert ESMO - Eur. Oncology